Cenobamate shown to improve quality of life beyond reducing seizures

[Financial News] A study has found that cenobamate, SK Biopharmaceuticals' epilepsy treatment sold in the United States under the brand name Xcopri, not only reduces seizures but also improves patients' quality of life.
According to the pharmaceutical and biotech industry on the 31st, the international journal Epilepsy & Behavior published a study by a research team at Vall d'Hebron University Hospital in Barcelona, Spain. The team analyzed six months of changes after cenobamate treatment in 106 adult patients with refractory epilepsy.
The study found that after cenobamate was administered, patients' average monthly seizure frequency fell from three before treatment to 0.66 six months later. That represented a reduction of about 78%. A total of 26.5% of patients achieved complete seizure freedom, with no seizures during the six-month period.
The research team also assessed patients' health-related quality of life alongside seizure frequency. Using tools such as the 36-Item Short Form Health Survey (SF-36), the analysis found a significant link between reduced seizure frequency and improvements in mental health.
Epilepsy can restrict daily life not only because of seizures themselves, but also because of the uncertainty of not knowing when a seizure may occur. Some activities, including driving and swimming, may be limited, and patients may also feel psychological strain in social settings and personal relationships. As a result, when evaluating treatment effectiveness, changes in quality of life are used as a key indicator alongside seizure reduction.
The study is seen as meaningful because it examined cenobamate's effects not only in terms of seizure suppression, but also in terms of patients' perceived health status and quality of life.
The importance of quality of life is also growing in the process of evaluating the clinical value of new drugs. In health care, quality-adjusted life year (QALY) is used to reflect not only treatment efficacy and survival time, but also the period during which a person lives in good health. It is also one of the key indicators in pharmaceutical economic evaluations in South Korea and abroad.
Cenobamate is an epilepsy treatment developed by SK Biopharmaceuticals and sold in the United States under the brand name Xcopri. Through this study, its clinical benefits were analyzed not only in terms of seizure reduction but also in terms of quality of life.
An industry source said, "In epilepsy treatment, it is important not only to reduce seizures but also to help patients recover as much of their daily lives as possible." The source added, "Clinical data showing both seizure reduction and improved quality of life could be used to assess the value of a treatment."
[email protected] Jung Sang-hee Reporter